PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer

Takeshi Hisamatsu, Michael McGuire, Sherry Wu, Rajesha Rupaimoole, Sunila Pradeep, Emine Bayraktar, Kyunghee Noh, Wei Hu, Jean M. Hansen, Yasmin Lyons, Kshipra M. Gharpure, Archana S. Nagaraja, Lingegowda S. Mangala, Takashi Mitamura, Cristian Rodriguez-Aguayo, Young Gyu Eun, Johnathon Rose, Geoffrey Bartholomeusz, Cristina Ivan, Ju-Seog Lee & 5 others Koji Matsuo, Michael Frumovitz, Kwong K Wong, Gabriel Lopez, Anil K Sood

Research output: Contribution to journalArticle

Abstract

For mucinous ovarian cancer (MOC), standard platinum-based therapy is largely ineffective. We sought to identify possible mechanisms of oxaliplatin resistance of MOC and develop strategies to overcome this resistance. A kinome-based siRNA library screen was carried out using human MOC cells to identify novel targets to enhance the efficacy of chemotherapy. In vitro and in vivo validations of antitumor effects were performed using mouse MOC models. Specifically, the role of PRKRA/PACT in oxaliplatin resistance was interrogated. We focused on PRKRA, a known activator of PKR kinase, and its encoded protein PACT because it was one of the five most significantly downregulated genes in the siRNA screen. In orthotopic mouse models of MOC, we observed a significant antitumor effect of PRKRA siRNA plus oxaliplatin. In addition, expression of miR-515-3p was regulated by PACT–Dicer interaction, and miR-515-3p increased the sensitivity of MOC to oxaliplatin. Mechanistically, miR-515-3p regulated chemosensitivity, in part, by targeting AXL. The PRKRA/PACT axis represents an important therapeutic target in MOC to enhance sensitivity to oxaliplatin.

LanguageEnglish (US)
Pages162-172
Number of pages11
JournalMolecular cancer therapeutics
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

oxaliplatin
Ovarian Neoplasms
Small Interfering RNA
Platinum
Phosphotransferases
Down-Regulation
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer. / Hisamatsu, Takeshi; McGuire, Michael; Wu, Sherry; Rupaimoole, Rajesha; Pradeep, Sunila; Bayraktar, Emine; Noh, Kyunghee; Hu, Wei; Hansen, Jean M.; Lyons, Yasmin; Gharpure, Kshipra M.; Nagaraja, Archana S.; Mangala, Lingegowda S.; Mitamura, Takashi; Rodriguez-Aguayo, Cristian; Eun, Young Gyu; Rose, Johnathon; Bartholomeusz, Geoffrey; Ivan, Cristina; Lee, Ju-Seog; Matsuo, Koji; Frumovitz, Michael; Wong, Kwong K; Lopez, Gabriel; Sood, Anil K.

In: Molecular cancer therapeutics, Vol. 18, No. 1, 01.01.2019, p. 162-172.

Research output: Contribution to journalArticle

Hisamatsu, T, McGuire, M, Wu, S, Rupaimoole, R, Pradeep, S, Bayraktar, E, Noh, K, Hu, W, Hansen, JM, Lyons, Y, Gharpure, KM, Nagaraja, AS, Mangala, LS, Mitamura, T, Rodriguez-Aguayo, C, Eun, YG, Rose, J, Bartholomeusz, G, Ivan, C, Lee, J-S, Matsuo, K, Frumovitz, M, Wong, KK, Lopez, G & Sood, AK 2019, 'PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer', Molecular cancer therapeutics, vol. 18, no. 1, pp. 162-172. https://doi.org/10.1158/1535-7163.MCT-17-1050
Hisamatsu T, McGuire M, Wu S, Rupaimoole R, Pradeep S, Bayraktar E et al. PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer. Molecular cancer therapeutics. 2019 Jan 1;18(1):162-172. https://doi.org/10.1158/1535-7163.MCT-17-1050
Hisamatsu, Takeshi ; McGuire, Michael ; Wu, Sherry ; Rupaimoole, Rajesha ; Pradeep, Sunila ; Bayraktar, Emine ; Noh, Kyunghee ; Hu, Wei ; Hansen, Jean M. ; Lyons, Yasmin ; Gharpure, Kshipra M. ; Nagaraja, Archana S. ; Mangala, Lingegowda S. ; Mitamura, Takashi ; Rodriguez-Aguayo, Cristian ; Eun, Young Gyu ; Rose, Johnathon ; Bartholomeusz, Geoffrey ; Ivan, Cristina ; Lee, Ju-Seog ; Matsuo, Koji ; Frumovitz, Michael ; Wong, Kwong K ; Lopez, Gabriel ; Sood, Anil K. / PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer. In: Molecular cancer therapeutics. 2019 ; Vol. 18, No. 1. pp. 162-172.
@article{36f22ba3478844c9b3a2f2e478802306,
title = "PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer",
abstract = "For mucinous ovarian cancer (MOC), standard platinum-based therapy is largely ineffective. We sought to identify possible mechanisms of oxaliplatin resistance of MOC and develop strategies to overcome this resistance. A kinome-based siRNA library screen was carried out using human MOC cells to identify novel targets to enhance the efficacy of chemotherapy. In vitro and in vivo validations of antitumor effects were performed using mouse MOC models. Specifically, the role of PRKRA/PACT in oxaliplatin resistance was interrogated. We focused on PRKRA, a known activator of PKR kinase, and its encoded protein PACT because it was one of the five most significantly downregulated genes in the siRNA screen. In orthotopic mouse models of MOC, we observed a significant antitumor effect of PRKRA siRNA plus oxaliplatin. In addition, expression of miR-515-3p was regulated by PACT–Dicer interaction, and miR-515-3p increased the sensitivity of MOC to oxaliplatin. Mechanistically, miR-515-3p regulated chemosensitivity, in part, by targeting AXL. The PRKRA/PACT axis represents an important therapeutic target in MOC to enhance sensitivity to oxaliplatin.",
author = "Takeshi Hisamatsu and Michael McGuire and Sherry Wu and Rajesha Rupaimoole and Sunila Pradeep and Emine Bayraktar and Kyunghee Noh and Wei Hu and Hansen, {Jean M.} and Yasmin Lyons and Gharpure, {Kshipra M.} and Nagaraja, {Archana S.} and Mangala, {Lingegowda S.} and Takashi Mitamura and Cristian Rodriguez-Aguayo and Eun, {Young Gyu} and Johnathon Rose and Geoffrey Bartholomeusz and Cristina Ivan and Ju-Seog Lee and Koji Matsuo and Michael Frumovitz and Wong, {Kwong K} and Gabriel Lopez and Sood, {Anil K}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-17-1050",
language = "English (US)",
volume = "18",
pages = "162--172",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer

AU - Hisamatsu, Takeshi

AU - McGuire, Michael

AU - Wu, Sherry

AU - Rupaimoole, Rajesha

AU - Pradeep, Sunila

AU - Bayraktar, Emine

AU - Noh, Kyunghee

AU - Hu, Wei

AU - Hansen, Jean M.

AU - Lyons, Yasmin

AU - Gharpure, Kshipra M.

AU - Nagaraja, Archana S.

AU - Mangala, Lingegowda S.

AU - Mitamura, Takashi

AU - Rodriguez-Aguayo, Cristian

AU - Eun, Young Gyu

AU - Rose, Johnathon

AU - Bartholomeusz, Geoffrey

AU - Ivan, Cristina

AU - Lee, Ju-Seog

AU - Matsuo, Koji

AU - Frumovitz, Michael

AU - Wong, Kwong K

AU - Lopez, Gabriel

AU - Sood, Anil K

PY - 2019/1/1

Y1 - 2019/1/1

N2 - For mucinous ovarian cancer (MOC), standard platinum-based therapy is largely ineffective. We sought to identify possible mechanisms of oxaliplatin resistance of MOC and develop strategies to overcome this resistance. A kinome-based siRNA library screen was carried out using human MOC cells to identify novel targets to enhance the efficacy of chemotherapy. In vitro and in vivo validations of antitumor effects were performed using mouse MOC models. Specifically, the role of PRKRA/PACT in oxaliplatin resistance was interrogated. We focused on PRKRA, a known activator of PKR kinase, and its encoded protein PACT because it was one of the five most significantly downregulated genes in the siRNA screen. In orthotopic mouse models of MOC, we observed a significant antitumor effect of PRKRA siRNA plus oxaliplatin. In addition, expression of miR-515-3p was regulated by PACT–Dicer interaction, and miR-515-3p increased the sensitivity of MOC to oxaliplatin. Mechanistically, miR-515-3p regulated chemosensitivity, in part, by targeting AXL. The PRKRA/PACT axis represents an important therapeutic target in MOC to enhance sensitivity to oxaliplatin.

AB - For mucinous ovarian cancer (MOC), standard platinum-based therapy is largely ineffective. We sought to identify possible mechanisms of oxaliplatin resistance of MOC and develop strategies to overcome this resistance. A kinome-based siRNA library screen was carried out using human MOC cells to identify novel targets to enhance the efficacy of chemotherapy. In vitro and in vivo validations of antitumor effects were performed using mouse MOC models. Specifically, the role of PRKRA/PACT in oxaliplatin resistance was interrogated. We focused on PRKRA, a known activator of PKR kinase, and its encoded protein PACT because it was one of the five most significantly downregulated genes in the siRNA screen. In orthotopic mouse models of MOC, we observed a significant antitumor effect of PRKRA siRNA plus oxaliplatin. In addition, expression of miR-515-3p was regulated by PACT–Dicer interaction, and miR-515-3p increased the sensitivity of MOC to oxaliplatin. Mechanistically, miR-515-3p regulated chemosensitivity, in part, by targeting AXL. The PRKRA/PACT axis represents an important therapeutic target in MOC to enhance sensitivity to oxaliplatin.

UR - http://www.scopus.com/inward/record.url?scp=85059497097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059497097&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-1050

DO - 10.1158/1535-7163.MCT-17-1050

M3 - Article

VL - 18

SP - 162

EP - 172

JO - Molecular Cancer Therapeutics

T2 - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -